Mummy, David GColeman, Erika MWang, ZiyiBier, Elianna ALu, JunlanDriehuys, BastiaanHuang, Yuh-Chin2023-08-022023-08-022021-091053-18071522-2586https://hdl.handle.net/10161/28663<h4>Background</h4>Hyperpolarized ¹²⁹ Xe magnetic resonance imaging (MRI) provides a non-invasive assessment of regional pulmonary gas exchange function. This technique has demonstrated that chronic obstructive pulmonary disease (COPD) patients exhibit ventilation defects, reduced interstitial barrier tissue uptake, and poor transfer to capillary red blood cells (RBCs). However, the behavior of these measurements following therapeutic intervention is unknown.<h4>Purpose</h4>To characterize changes in ¹²⁹ Xe gas transfer function following administration of an inhaled long-acting beta-agonist/long-acting muscarinic receptor antagonist (LABA/LAMA) bronchodilator.<h4>Study type</h4>Prospective.<h4>Population</h4>Seventeen COPD subjects (GOLD II/III classification per Global Initiative for Chronic Obstructive Lung Disease criteria) were imaged before and after 2 weeks of LABA/LAMA therapy.<h4>Field strength/sequences</h4>Dedicated ventilation imaging used a multi-slice 2D gradient echo sequence. Three-dimensional images of ventilation, barrier uptake, and RBC transfer used an interleaved, radial, 1-point Dixon sequence. Imaging was acquired at 3 T.<h4>Assessment</h4>¹²⁹ Xe measurements were quantified before and after LABA/LAMA treatment by ventilation defect + low percent (ven_{def + low} ) and by barrier uptake and RBC transfer relative to a healthy reference population (bar_%ref and RBC_%ref ). Pulmonary function tests, including diffusing capacity of the lung for carbon monoxide (DL_CO ), were also performed before and after treatment.<h4>Statistical tests</h4>Paired t-test, Pearson correlation coefficient (r).<h4>Results</h4>Baseline ven_{def + low} was 57.8 ± 8.4%, bar_%ref was 73.2 ± 19.6%, and RBC_%ref was 36.5 ± 13.6%. Following treatment, ven_{def + low} decreased to 52.5 ± 10.6% (P < 0.05), and improved in 14/17 (82.4%) of subjects. However, RBC_%ref decreased in 10/17 (58.8%) of subjects. Baseline measurements of bar_%ref and DL_CO were correlated with the degree of post-treatment change in ven_{def + low} (r = -0.49, P < 0.05 and r = -0.52, P < 0.05, respectively).<h4>Conclusion</h4>LABA/LAMA therapy tended to preferentially improve ventilation in subjects whose ¹²⁹ Xe barrier uptake and DL_CO were relatively preserved. However, newly ventilated regions often revealed RBC transfer defects, an aspect of lung function opaque to spirometry. These microvasculature abnormalities must be accounted for when assessing the effects of LABA/LAMA therapy.<h4>Level of evidence</h4>1 TECHNICAL EFFICACY STAGE: 4.LungHumansPulmonary Disease, Chronic ObstructiveBronchodilator AgentsMagnetic Resonance ImagingAdministration, InhalationProspective StudiesJournal article2023-08-02